Background: Factors contributing to the development of alexithymia and the nature of alexithymia’s relation with trait negative and positive affectivity are unclear. In this study, a twin approach was used to examine the degree of genetic and environmental contributions to the different facets of alexithymia, and the nature of their relations to trait negative and positive affectivity. Method: Forty-five monozygotic and 32 same-sex dizygotic twin pairs completed the Toronto Alexithymia Scale-20, the Eysenck Personality Inventory, and a zygosity questionnaire. Results: Model fitting analyses indicated that familial influences contributed significantly to all three facets of alexithymia. Parameter estimates and intraclass correlations suggested, though could not confirm, that it was shared environmental factors that contributed to difficulty identifying and communicating emotions (ID and COM), but shared genetic factors that contributed to externally oriented thinking (EOT). Between-twin cross-trait twin analyses revealed strong correlations between ID and neuroticism, and between COM and extraversion, and suggested that it is shared familial influences which account for these associations. Conclusions: The results of this study indicate that: (a) the different facets of alexithymia are influenced by familial factors; (b) the previously noted associations between ID and COM and trait affectivity are not merely methodological artifacts; and (c) the associations between ID and COM and trait affectivity are influenced by familial factors. The results also suggest that ID and COM are largely influenced by shared environmental factors, but that EOT is influenced by genetic factors.

Keywords:
Alexithymia, Twins, Genetics, Shared environment, Trait affectivity, Neuroticism, Extraversion
1.
Taylor GJ, Bagby RM, Parker JD: The alexithymia construct: A potential paradigm for psychological medicine. Psychosomatics 1991;32:153–164.
2.
Taylor GJ, Bagby RM, Ryan DP, Parker JD: Validation of the alexithymia construct: A measurement based approach. Can J Psychiatry 1990;35:290–297.
3.
Sifneos PE: Short-Term Psychotherapy and Emotional Crisis. Cambridge, Harvard University Press, 1972.
4.
Taylor GJ: Alexithymia: Concept, measurement, and implications for treatment. Am J Psychiatry 1984;141:725–732.
5.
Todarello O, La Pesa MW, Zaka S, Martino V, Lattanzio E: Alexithymia and breast cancer: Survey of 200 women undergoing mammography. Psychother Psychosom 1989;51:51–55.
6.
Abramson L, McCleland DC, Brown D, Kelner S: Alexithymic characteristics and metabolic control in diabetic and healthy adults. J Nerv Ment Dis 1991;179:490–494.
7.
Hendryx MS, Haviland MG, Shaw DG: Dimensions of alexithymia and their relationship to anxiety and depression. J Pers Assess 1991;56:227–237.
8.
Krystal JH, Giller EL Jr, Cicchetti DV: Assessment of alexithymia on post-traumatic stress disorder and somatic illness: Introduction of a reliable measure. Psychosom Med 1986;48:84–94.
9.
Taylor GJ, Bagby RM, Parker JD: Disorders of Affect Regulation: Alexithymia in Medical and Psychiatric Illness. New York, Cambridge University Press, 1997.
10.
Heiberg A, Heiberg A: Alexithymia – an inherited trait: A study of twins. Psychother Psychosom 1976;28:221–225.
11.
Heiberg A, Heiberg A: A possible genetic contribution to the alexithymia trait. Psychother Psychosom 1978;30:205–210.
12.
Lumley MA, Mader G, Gramzow J, Papineau K: Family factors related to alexithymia characteristics. Psychosom Med 1996;58:211–216.
13.
Mayer JD, DiPaolo M, Salovey P: Perceiving affective content in ambiguous visual stimuli: A component of emotional intelligence. J Pers Assess 1990;54:772–781.
14.
Parker JD, Bagby RM, Taylor GJ: Toronto Alexithymia Scale, EPQ, and self-report measures of somatic complaints. Pers Indiv Diff 1989;10:599–604.
15.
Berenbaum H, James T: Correlates and retrospectively reported antecedents of alexithymia. Psychosom Med 1994;56:353–359.
16.
Waller NG, Ross CA: The prevalence and biometric structure of pathological dissociation in the general population: Taxonomic and behavior genetic findings. J Abnorm Psychol 1997;106:499–510.
17.
Berenbaum H: Childhood abuse, alexithymia and personality disorder. J Psychosom Res 1996;41:585–595.
18.
Fukunishi I, Kawamura N, Ishikawa T, Ago Y, Sei H, Morita Y, Rahe RH: Mothers’ low care in the development of alexithymia: A preliminary study in Japanese college students. Psychol Rep 1997;80:143–146.
19.
Dion KL: Ethnolinguistic correlates of alexithymia: Toward a cultural perspective. J Psychosom Res 1996;41:531–539.
20.
Parker JDA, Babgy RM, Taylor GJ: Alexithymia and depression: Distinct or overlapping constructs. Compr Psychiatry 1991;32:387–394.
21.
Deneve KM, Cooper H: The happy personality: A meta-analysis of 137 personality traits and subjective well-being. Psychol Bull 1998;124:197–229.
22.
Watson D, Clark LE: On traits and temperament: General and specific factors of emotional experience and their relation to the five-factor model. J Pers 1992;60:441–476.
23.
Raiekkoenen K, Matthews KA, Flory JD, Owens JF, Gump BB: Effects of optimism, pessimism, and trait anxiety on ambulatory blood pressure and mood during everyday life. J Pers Soc Psychol 1999;76:104–113.
24.
Meyers DG, Diener E: Who is happy? Psychol Sci 1995;6:10–19.
25.
Argyle M: Is happiness a cause of health? Psychol Health 1997;12:769–781.
26.
Ryff CD, Singer BH: Biopsychosocial challenges of the new millennium. Psychother Psychosom 2000;69:170–177.
27.
Valera EM, Heller W, Berenbaum H: A twin study of individual differences in perceptual asymmetry. Laterality 1999;4:299–312.
28.
Goldsmith HH: A zygosity questionnaire for young twins: A research note. Behav Genet 1991;21:257–269.
29.
Magnus P, Berg K, Nance WE: Predicting zygosity in Norwegian twin pairs born 1915–1960. Clin Genet 1983;24:103–112.
30.
Sarna S, Kaprio J, Sistonen P, Koskenvuo M: Diagnosis of twin zygosity by mailed questionnaire. Hum Hered 1978;28:241–254.
31.
Nichols RC, Bilbro WC: The diagnosis of twin zygosity. Acta Genet 1966;16:265–275.
32.
Cederlof R, Friberg L, Jonsson E, Kaij L: Studies on similarity diagnosis in twins with the aid of mailed questionnaires. Acta Genet 1961;11:338–362.
33.
Bagby RM, Parker JD, Taylor GJ: The twenty-item Toronto alexithymia scale. I. Item selection and cross-validation of the factor structure. J Psychosom Res 1994;38:23–32.
34.
Bagby RM, Taylor GJ, Parker JD: The twenty-item Toronto alexithymia scale. II. Convergent, discriminant, and concurrent validity. J Psychosom Res 1994;38:33–40.
35.
Eysenck HJ, Eysenck SB: Manual of the Eysenck Personality Inventory. San Diego, Educational and Industrial Testing Service, 1968.
36.
Eaves LJ, Eysenck HJ, Martin NG: The classical approach: Early twin studies of personality; in Genes, Culture and Personality: An Empirical Approach. San Diego, Academic Press, 1989.
37.
Neale MC: MX: Statistical Modeling, ed 3. Richmond, Department of Psychiatry, 1995.
38.
DeFries JC, Fulker DW: Multiple regression analysis of twin data. Behav Genet 1985;15:467–473.
39.
Rose RJ: Genetic and environmental variance in content dimensions of the MMPI. J Pers Soc Psychol 1988;55:302–311.
40.
Henderson ND: Human behavior genetics. Annu Rev Psychol 1982;33:403–440.
© 2001 S. Karger AG, Basel
2001
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.